|
|
Volumn 130, Issue 10, 2008, Pages 380-392
|
|
Current strategies in the treatment of renal-cell cancer: Targeted therapies;Estrategias actuales en el tratamiento del carcinoma de células renales: Fármacos dirigidos a dianas moleculares
|
|
Author keywords
HIF; Molecular targets; PDGF; Renal cell carcinoma; Sunitinib; VEGF; Von Hippel Lindau
|
|
Indexed keywords
ALPHA INTERFERON;
AXITINIB;
BEVACIZUMAB;
CAPECITABINE;
CETUXIMAB;
ERLOTINIB;
EVEROLIMUS;
FLUOROURACIL;
GEFITINIB;
GEMCITABINE;
GENE PRODUCT;
HYPOXIA INDUCIBLE FACTOR 1;
IMATINIB;
INTERLEUKIN 2;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
MEDROXYPROGESTERONE ACETATE;
PLACEBO;
PLATELET DERIVED GROWTH FACTOR;
RAPAMYCIN;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
VASCULOTROPIN;
VATALANIB;
VINBLASTINE;
VON HIPPEL LINDAU PROTEIN;
CANCER ADJUVANT THERAPY;
CANCER CHEMOTHERAPY;
CANCER CLASSIFICATION;
CANCER COMBINATION CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER EPIDEMIOLOGY;
CANCER IMMUNOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SURGERY;
CARCINOGENESIS;
CLINICAL FEATURE;
CONTINUOUS INFUSION;
DIAGNOSTIC PROCEDURE;
DRUG TARGETING;
GENE LOSS;
GENE MUTATION;
GENE SILENCING;
GENE TARGETING;
HISTOPATHOLOGY;
HUMAN;
KIDNEY CARCINOMA;
MULTIPLE CYCLE TREATMENT;
PATHOLOGICAL ANATOMY;
PREVALENCE;
PROGNOSIS;
REVIEW;
TRANSACTIVATION;
TUMOR SUPPRESSOR GENE;
TUMOR VASCULARIZATION;
VON HIPPEL LINDAU GENE;
|
|
EID: 42549087692
PISSN: 00257753
EISSN: 15788989
Source Type: Journal
DOI: 10.1157/13117476 Document Type: Review |
|
Times cited : (4)
|
|
References (160)
|
